{
  "figure_2": "Management of ALN involvement in EBC. Burgundy box: general categories or stratification; orange boxes: surgery; blue box: systemic anticancer therapy; dark green boxes: radiotherapy; turquoise box: combination of treatments or other systemic treatments; white boxes: other aspects of management.\nALN, axillary lymph node; ALND, axillary lymph node dissection; c, clinical; ChT, chemotherapy; CT, computed tomography; EBC, early breast cancer: i, imaging; ITC, isolated tumour cell; LN, lymph node; MDT, multidisciplinary team; MRI, magnetic resonance imaging; N, node; p, pathological; PET, positron emission tomography; PST, primary systemic therapy; RT, radiotherapy; SLN, sentinel lymph node; SLNB, sentinel lymph node biopsy; TAD, targeted axillary dissection; US, ultrasound. .\naDiscuss in MDT whether number of LNs is important for systemic therapy allocation.\nbSee Figure 1 for an overview of primary surgery and neoadjuvant therapy indications.\ncImaging (axillary US is preferred but MRI and PET–CT may be used in specific cases where more detailed imaging is required).\ndRefers to ACOSOG-Z0011 trial eligibility criteria.75\neRefers to AMAROS trial eligibility criteria.76 OTOASOR trial criteria can also be considered.77\nfInflammatory breast cancer and patients with N2 or N3 stage disease should receive ALND unless otherwise defined in a clinical trial.\ngIf ITCs are detected, consider axillary and locoregional RT as an alternative to ALND if an impact on adjuvant systemic treatments is not anticipated.",
  "figure_3": "Management of HR-positive, HER2-negative EBC. Burgundy box: general categories or stratification; blue boxes: systemic anticancer therapy; turquoise boxes: combination of treatments or other systemic treatments; white boxes: other aspects of management; dashed line: optional recommendation.\nChT, chemotherapy; CPS+EG, pretreatment clinical stage and post-treatment pathological stage, estrogen receptor and tumour grade; EBC, early breast cancer; EMA, European Medicines Agency; ESCAT, ESMO Scale for Clinical Actionability of molecular Targets; ESMO, European Society for Medical Oncology; ET, endocrine therapy; FDA, Food and Drug Administration; gBRCA1/2; germline BRCA1/2; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; m, mutation; MCBS, ESMO-Magnitude of Clinical Benefit Scale; N, node; pCR, pathological complete response; wt, wild type.\naSee Figure 1 for the role of surgery in HR-positive, HER2-negative EBC.\nbStage N1 with primary tumour >5 cm, and/or grade 3 and/or Ki-67 ≥20%.\ncESMO-MCBS v1.178 was used to calculate scores for new therapies/indications approved by the EMA or FDA. The scores have been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee (https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-evaluation-forms).\ndIf gBRCA1/2 testing is appropriate and feasible.\nePatients with HR-positive tumours and non-pCR after neoadjuvant ChT require a CPS+EG score ≥3 to receive olaparib.\nfESCAT scores apply to alterations from genomic-driven analyses only. These scores have been defined by the guideline authors and assisted as needed by the ESMO Translational Research and Precision Medicine Working Group.79",
  "figure_4": "Management of HER2-positive EBC. Burgundy box: general categories or stratification; blue box: systemic anticancer therapy; turquoise box: combination of treatments or other systemic treatments; white boxes: other aspects of management.\nc, clinical; ChT, chemotherapy; EBC, early breast cancer; EMA, European Medicines Agency; ESCAT, ESMO Scale for Clinical Actionability of molecular Targets; ESMO, European Society for Molecular Oncology; ET, endocrine therapy; FDA, Food and Drug Administration; HER2, human epidermal growth factor receptor 2; HP, trastuzumab–pertuzumab: HR, hormone receptor; MCBS, ESMO-Magnitude of Clinical Benefit Scale; N, node; p, pathological; pCR, pathological complete response; RT, radiotherapy; T, tumour; T-DM1, trastuzumab emtansine.\naTumours <2 cm can be considered for neoadjuvant therapy.\nbESMO-MCBS v1.178 was used to calculate scores for new therapies/indications approved by the EMA or FDA. The scores have been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee (https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-evaluation-forms).\ncESCAT score I-A if HER2 gene amplification by FISH/chromogenic in situ hybdidisation. ESCAT scores apply to alterations from genomic-driven analyses only. These scores have been defined by the guideline authors and assisted as needed by the ESMO Translational Research and Precision Medicine Working Group.79",
  "figure_5": "Management of early TNBC. Burgundy box: general categories or stratification; blue box: systemic anticancer therapy; turquoise box: combination of treatments or other systemic treatments; white boxes: other aspects of management; dashed line: optional recommendation.\nAC, doxorubicin–cyclophosphamide; c, clinical; ChT, chemotherapy; CPG, Clinical Practice Guideline; EC, epirubicin–cyclophosphamide; EMA, European Medicines Agency; ER, estrogen receptor; ESCAT, ESMO Scale for Clinical Actionability of molecular Targets; ESMO, European Society for Molecular Oncology; ER; estrogen receptor; ET, endocrine therapy; FDA, Food and Drug Administration; gBRCA1/2, germline BRCA1/2; gBRCA1/2m, germline BRCA1/2; mutation; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; ICI, immune checkpoint inhibitor; m, mutation; MCBS, ESMO-Magnitude of Clinical Benefit Scale; N, node; p, pathological; pCR, pathological complete response; PgR, progesterone receptor; RT, radiotherapy; T, tumour; TNBC, triple-negative breast cancer; wt, wild type.\naSee the ESMO CPG for risk reduction and screening of cancer in hereditary breast–ovarian cancer syndromes.80\nbHER2– tumours with 1%-9% ER and/or PgR expression (ER-low/PgR-low) are a heterogeneous group, some of which behave biologically similarly to TNBC; therapeutic strategies should be adjusted to this specific situation since this might lead to a higher response to ChT and to reduced efficacy of ET, compared with classical HR+ breast cancer [II, B].\ncThese evidence-based regimens without ICIs are sequential: anthracycline-based therapy followed by a taxane or taxane–carboplatin or vice versa.\ndAccording to OlympiA inclusion criteria.81\neESMO-MCBS v1.178 was used to calculate scores for new therapies/indications approved by the EMA or FDA. The scores have been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee (https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-evaluation-forms).\nfIndicated as adjuvant therapy for patients with gBRCA1/2m tumours and non-pCR or _pT2 or _pN1 if treated with initial surgery.\ngESCAT scores apply to alterations from genomic-driven analyses only. These scores have been defined by the guideline authors and assisted as needed by the ESMO Translational Research and Precision Medicine Working Group.79 ESCAT applicable if HER2 gene amplification by FISH.\nhOnly if pembrolizumab was given preoperatively.\niOnly for ICI-naïve patients.",
  "figure_6": "Management of adjuvant endocrine therapy in HR-positive EBC. Burgundy box: general categories or stratification; blue boxes: systemic anticancer therapy; turquoise box: combination of treatments or other systemic treatments; white boxes: other aspects of management. AI, aromatase inhibitor; EBC, early breast cancer; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; OFS, ovarian function suppression.\naSee Figure 1 for the role of surgery in HR-positive, HER2-negative EBC.\nbTamoxifen can be given for lower-risk tumours or if AIs are not tolerated [I, A]."
}